此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin Diseases (GUMIDIC)

Studio Sulla diversità Del Microbiota Intestinale Umano in Pazienti Con Patologie Infiammatorie Cutanee

This study will examine whether the gut bacteria of adults with inflammatory or immune-mediated skin diseases differ from those of healthy adults. It will include people with atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid, as well as healthy controls.

Participants will provide a stool sample and complete a short food diary. The study team will analyze the bacteria in the samples and compare the results between the disease groups and healthy controls. Participants with a skin disease will be asked to provide a second stool sample and complete follow-up assessments about six months later; healthy controls will provide one sample. The study will also examine whether changes in gut bacteria are related to skin disease severity, diet, and other collected health information.

研究概览

研究类型

观察性的

注册 (估计的)

694

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adults aged 18 years or older with one of eight specialist-confirmed inflammatory or immune-mediated skin diseases, plus healthy adult controls without those diseases. Participants are recruited through the Dermatology service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.

描述

Inclusion Criteria:

  • Age 18 years or older.
  • Able and willing to provide informed consent.
  • For patient groups: specialist-confirmed diagnosis of atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid.
  • For healthy controls: no diagnosis of the skin diseases studied.

Exclusion Criteria:

  • Unable to provide informed consent or complete the study procedures.
  • Systemic antibiotic treatment within 8 weeks before recruitment or during follow-up.
  • Previous intestinal surgery.
  • Inflammatory bowel disease, constipation, or diarrhea.
  • Long-term alcohol use.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Atopic Dermatitis

Adults aged 18 years or older with dermatologist-confirmed atopic dermatitis. Participants provide a stool sample and complete study assessments at baseline and about six months later.

Psoriasis

Adults aged 18 years or older with dermatologist-confirmed psoriasis. Participants provide a stool sample and complete study assessments at baseline and about six months later.

Hidradenitis Suppurativa

Adults aged 18 years or older with dermatologist-confirmed hidradenitis suppurativa. Participants provide a stool sample and complete study assessments at baseline and about six months later.

Vitiligo

Adults aged 18 years or older with dermatologist-confirmed vitiligo. Participants provide a stool sample and complete study assessments at baseline and about six months later.

Acne

Adults aged 18 years or older with dermatologist-confirmed acne. Participants provide a stool sample and complete study assessments at baseline and about six months later.

Pemphigus

Adults aged 18 years or older with dermatologist-confirmed pemphigus. Participants provide a stool sample and complete study assessments at baseline and about six months later.

Bullous Pemphigoid

Adults aged 18 years or older with dermatologist-confirmed bullous pemphigoid. Participants provide a stool sample and complete study assessments at baseline and about six months later.

Healthy Controls

Adults aged 18 years or older who do not have the skin diseases studied. Participants provide one stool sample and complete study assessments at baseline.

Alopecia Areata

dults aged 18 years or older with dermatologist-confirmed alopecia areata. Participants provide a stool sample and complete study assessments at baseline and about six months later.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Relative abundance of Bifidobacteriaceae in stool
大体时间:Baseline (T1)

Compare the relative abundance of the bacterial family Bifidobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. Relative abundance is the number of sequences assigned to Bifidobacteriaceae divided by the total number of bacterial sequences.

Baseline (T1)

次要结果测量

结果测量
措施说明
大体时间
Relative abundance of Enterobacteriaceae in stool in the combined patient group
大体时间:Baseline (T1)

Compare the relative abundance of Enterobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls.

Baseline (T1)
Relative abundance of Bifidobacteriaceae by skin-disease group
大体时间:Baseline (T1)

Compare stool Bifidobacteriaceae relative abundance between each disease group-atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, and bullous pemphigoid-and healthy controls.

Baseline (T1)
Relative abundance of Enterobacteriaceae by skin-disease group
大体时间:Baseline (T1)

Compare stool Enterobacteriaceae relative abundance between each of the eight disease groups and healthy controls.

Baseline (T1)
Change in stool Bifidobacteriaceae and Enterobacteriaceae over time
大体时间:Baseline (T1) to 6 months (T2)

Assess within-person changes in the relative abundance of Bifidobacteriaceae and Enterobacteriaceae between T1 and T2 in participants with skin disease.

Baseline (T1) to 6 months (T2)
Associations between gut bacteria and disease-related measures
大体时间:Baseline (T1) and 6 months (T2)

Explore associations between Bifidobacteriaceae and Enterobacteriaceae relative abundance and disease activity scores, psychological impact scores, available routine laboratory markers, dietary intake, and anthropometric measures, as specified in the protocol.

Baseline (T1) and 6 months (T2)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月11日

初级完成 (估计的)

2028年7月31日

研究完成 (估计的)

2029年1月31日

研究注册日期

首次提交

2026年11月11日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅